The Emergence of a JAK2 V617F‐mutated Clone in Myelodysplastic Syndrome is Associated with Disease Progression and Features of Myelofibrosis

Boris Zhong,L. Jeffrey Medeiros,Wei Wang
DOI: https://doi.org/10.1111/bjh.15984
2019-01-01
British Journal of Haematology
Abstract:A 70-year-old man with a history of myelodysplastic syndrome (MDS) with multilineage dysplasia presented with worsening pancytopenia 5 years after the initial diagnosis. A full blood count showed: white blood cells (WBC) 1·7 × 109/l, haemoglobin concentration (Hb) 85 g/l and platelets 40 × 109/l. Bone marrow aspiration and trephine biopsy (upper panel) showed a hypercellular marrow with increased and atypical megakaryocytes in a background of reticulin and collagen fibrosis (myelofibrosis grade-2 on a scale of 0–3) as well as osteosclerosis. Megakaryocytes formed clusters and most were enlarged with hyperchromatic nuclei and abnormal nuclear lobation, reminiscent of megakaryocytes seen in primary myelofibrosis. Next generation sequencing analysis of the bone marrow aspirate showed a JAK2 V617F mutation with a variant allele frequency of 9%. No TP53 mutation was detected. For comparison, we reviewed the previous MDS specimen (lower panel) from 5 years earlier, which showed many small and hypolobated megakaryocytes, consistent with MDS. Erythroid cells were also dysplastic (lower panel, insert). No background myelofibrosis was present. JAK2 V617F mutation was not detected using next generation sequencing analysis. His full blood count 5 years earlier was: WBC 8·3 × 109/l, Hb 108 g/l and platelets 87 × 109/l. In summary, the occurrence of a JAK2 V617F mutation in this case was associated with disease progression, including morphological changes in megakaryocytes, development of myelofibrosis and worsening pancytopenia. Although very rare, JAK2 V617F can be detected in MDS patients and, when detected, the differential diagnosis between MDS with fibrosis and primary myelofibrosis can be challenging. In MDS with JAK2 V617F, the mutation is often secondary with a relatively low variant allele frequency. Dysplasia, if present, also supports MDS.
What problem does this paper attempt to address?